Investing is rarely black and white, but one of the most enduring debates in equity markets is this: Do you chase the proven performers at a premium, or take a punt on the underpriced underdogs? In this episode, we’re putting that question to the test. Joining Livewire's Chris Conway are two seasoned portfolio managers, Hamish FitzSimons of AllianceBernstein and Dougal Maple-Brown from Maple-Brown Abbott. Together, they explore some of the ASX’s most closely watched names across key sectors, including banks, miners, healthcare, and consumer staples. But there's a twist. For each 'quality' name, Hamish and Dougal will assess the company in classic Buy Hold Sell style. Then, they’ll weigh up a potential 'value' alternative and tell us whether they prefer it. Which names offer true long-term defensiveness? Which ones are still too expensive despite recent drawdowns? And which cheaper stocks have what it takes to close the gap? Please note this episode was filmed on 2 July 2025.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related